Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model
NEW YORK (
) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.
Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Health Care Technology industry. The net income has significantly decreased by 188.5% when compared to the same quarter one year ago, falling from $0.69 million to -$0.61 million.
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Technology industry and the overall market, EPOCRATES INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has significantly decreased to -$1.91 million or 162.53% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- EPOCRATES INC has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. The company has reported a trend of declining earnings per share over the past two years. However, the consensus estimate suggests that this trend should reverse in the coming year. During the past fiscal year, EPOCRATES INC swung to a loss, reporting -$0.06 versus $0.17 in the prior year. This year, the market expects an improvement in earnings ($0.19 versus -$0.06).
- EPOC, with its decline in revenue, underperformed when compared the industry average of 12.8%. Since the same quarter one year prior, revenues slightly dropped by 2.1%. The declining revenue appears to have seeped down to the company's bottom line, decreasing earnings per share.
Epocrates, Inc. provides subscriptions for mobile drug reference tools and electronic health records to healthcare professionals, and interactive services to the healthcare industry. The company has a P/E ratio of -24.3, below the S&P 500 P/E ratio of 17.7. Epocrates has a market cap of $248.2 million and is part of the health care sector and health services industry. Shares are up 27.9% year to date as of the close of trading on Friday.
You can view the full
or get investment ideas from our
-- Written by a member of TheStreet Ratings Staff
FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!